公开(公告)号：US20210017553A1

公开(公告)日：2021-01-21

申请号：US16917099

申请日：2020-06-30

申请人： PFIZER INC.

发明人： Gregory Walter HILLER ,  Jeffrey Joseph MITCHELL ,  Bhanu Chandra MULUKUTLA ,  Pamela Mary PEGMAN

IPC分类号： C12P7/62 ,  C12P7/42 ,  C12P7/52 ,  C07K16/00 ,  C12P7/56 ,  C12P7/40 ,  C12P17/18

摘要： The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.

公开(公告)号：US20210017206A1

公开(公告)日：2021-01-21

申请号：US16980473

申请日：2019-03-14

申请人： Pfizer Inc.

发明人： Matthew Frank Brown ,  Ye Che ,  Anthony Marfat ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Timothy Allan Johnson ,  Richard Andrew Ewin ,  Daniel Paul Uccello ,  Usa Reilly ,  Tamim Fehme Braish

IPC分类号： C07F9/6558 ,  C07F9/58 ,  C07F5/04 ,  A61P31/04

摘要： The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20210017205A1

公开(公告)日：2021-01-21

申请号：US16980616

申请日：2019-03-14

申请人： Pfizer Inc.

发明人： Tamim Fehme Braish ,  Matthew Frank Brown ,  Ye Che ,  Richard Andrew Ewin ,  Timothy Allan Johnson ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Mark Stephen Plummer ,  Loren Michael Price ,  Usa Reilly ,  Daniel Uccello

IPC分类号： C07F9/58 ,  C07F5/02 ,  A61P31/04

摘要： The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20200375968A1

公开(公告)日：2020-12-03

申请号：US15931910

申请日：2020-05-14

申请人： Bristol-Myers Squibb Company ,  Pfizer Inc.

发明人： Jatin Patel ,  Charles Frost ,  Jingpin Jia ,  Chandra Vemavarapu

IPC分类号： A61K31/4545 ,  A61K9/20 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48

摘要： Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

公开(公告)号：US10851367B2

公开(公告)日：2020-12-01

申请号：US15347339

申请日：2016-11-09

申请人： Pfizer Inc. ,  The Regents of the University of California

发明人： Spiros Liras ,  Vincent Mascitti ,  Benjamin Aaron Thuma ,  Jennifer A. Doudna ,  Romain Rouet

IPC分类号： C12N9/22 ,  C12N9/96 ,  C12N15/90 ,  A61K47/54

摘要： The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US10829553B2

公开(公告)日：2020-11-10

申请号：US15581079

申请日：2017-04-28

申请人： PFIZER INC. ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Stefano V. Gulla ,  Christine Huard ,  Janet Elizabeth Buhlmann ,  Juan Carlos Almagro ,  Sreekumar R. Kodangattil ,  Steven A. Greenberg ,  Edward Roland Lavallie ,  Eric M. Bennett ,  Lidia Mosyak ,  James Perry Hall ,  Anthony John Coyle

IPC分类号： C07K16/24 ,  A61K39/00

摘要： The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.

公开(公告)号：US10829521B2

公开(公告)日：2020-11-10

申请号：US16713782

申请日：2019-12-13

申请人： PFIZER INC.

发明人： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark Edward Ruppen

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/00

摘要： In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

公开(公告)号：US10815240B2

公开(公告)日：2020-10-27

申请号：US16502703

申请日：2019-07-03

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20200325228A1

公开(公告)日：2020-10-15

申请号：US16742657

申请日：2020-01-14

申请人： PFIZER INC. ,  MERCK SHARP & DOHME CORP.

发明人： Jean-Francois Andre Martini ,  Jamal Christo Tarazi ,  Rodolfo Fleury Perini ,  David J. Mauro

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K31/4439 ,  A61K45/06 ,  C07K16/30

摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L 1.

公开(公告)号：US10800783B2

公开(公告)日：2020-10-13

申请号：US16251032

申请日：2019-01-17

申请人： Pfizer Inc.

发明人： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC分类号： A61K31/519 ,  A61K31/4375 ,  A61K31/4545 ,  C07D487/04 ,  C07D401/12 ,  C07D471/04 ,  C07D401/14

摘要： This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.